Martin Wermke

机构：Heidelberg University, Helmholtz-Zentrum Dresden-Rossendorf, University Hospital Heidelberg, Ford (Germany), National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Klinik und Poliklinik für Psychotherapie und Psychosomatik, Hochschule für Technik und Wirtschaft Dresden – University of Applied Sciences, Nationales Centrum für Tumorerkrankungen Dresden, Technische Universität Dresden · ORCID：0000-0002-4844-4087

发表论文 319 篇 · 总被引 8656 次 · h-index 44

代表论文

• First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer (2026 · New England Journal of Medicine · 被引 10)
• Phase 1a study results for IMA203CD8, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in ovarian cancer. (2026 · Journal of Clinical Oncology · 被引 2)
• Abstract LB-A003: Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: results from an ongoing Phase I trial (2026 · Cancer Immunology Research · 被引 2)
• Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer (2026 · JAMA Oncology · 被引 1)
• Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial (2026 · Nature Medicine · 被引 1)
• Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma. (2026 · Journal of Clinical Oncology · 被引 1)